Answers are grounded in this paper and cite their sources.
Staphylococcus aureus is a Gram-positive pathogen that possesses resistance factors responsible for the occurrence of several diseases, including those affecting the airways and gastrointestinal tract, causing osteomyelitis and systemic infections that increase mortality rates. Metronidazole is a drug with antiparasitic and antibacterial activity, and the phenolic compounds eugenol, dihydroeugenol, guaiacol, and phenol exhibit several therapeutic activities, one of which is antibacterial. Thus, eight compounds were synthesized by linking metronidazole with the aforementioned compounds, forming substances designated AD1–AD8. This study aimed to investigate the adjuvant potential of compounds AD1–AD8 in enhancing the action of ciprofloxacin and ethidium bromide against the S. aureus K2068 strain, considering the possible involvement of MepA efflux pump modulation, as well as to evaluate the direct antibacterial activity of these compounds. Broth microdilution assays and molecular docking studies were performed to assess antibacterial activity and inhibition of the MepA efflux pump. Compounds AD1–AD8 reduced the minimum inhibitory concentration (MIC) of ciprofloxacin and ethidium bromide, with molecular docking results demonstrating a possible inhibition of the MepA efflux pump. Overall, substances AD1–AD8 were able to significantly potentiate the action of the antibiotic and ethidium bromide due to the probable blockade of the resistance mechanism. The obtained results indicate the potential of compounds AD1–AD8 as therapeutic adjuvants in combating efflux pump–mediated bacterial resistance.
No takes yet. Share an insight, caveat, or question.
Sa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: